Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.
Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA; UK CHIC Study Steering Committee. Barber TJ, et al. Among authors: fisher m. Antivir Ther. 2011;16(6):805-14. doi: 10.3851/IMP1818. Antivir Ther. 2011. PMID: 21900712
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.
Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J, Fisher M, Orkin C, Schwenk A, Gilson R, Easterbrook P, Delpech V, Sabin CA; UK CHIC Study Group. Porter K, et al. Among authors: fisher m. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):202-5. doi: 10.1097/QAI.0b013e31815b1291. J Acquir Immune Defic Syndr. 2008. PMID: 17971709
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
Waters L, Fisher M, Winston A, Higgs C, Hadley W, Garvey L, Mandalia S, Perry N, Nicola M, Nelson M. Waters L, et al. Among authors: fisher m. AIDS. 2011 Jan 2;25(1):65-71. doi: 10.1097/QAD.0b013e328341685b. AIDS. 2011. PMID: 21099666 Clinical Trial.
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.
Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M. Williams I, et al. Among authors: fisher m. HIV Med. 2012 Sep;13 Suppl 2:1-85. doi: 10.1111/j.1468-1293.2012.01029.x. HIV Med. 2012. PMID: 22830364 Free article.
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P, Johnson M, Chadwick D, Nitsch D, Jones R, Sabin CA, Post FA; UK Collaborative HIV Cohort Study Steering Committee. Jose S, et al. Among authors: fisher m. J Infect Dis. 2014 Aug 1;210(3):363-73. doi: 10.1093/infdis/jiu107. Epub 2014 Feb 28. J Infect Dis. 2014. PMID: 24585896 Free PMC article.
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.
Sabin CA, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, Youle MS, Johnson MA, Fisher M, Scullard G, Easterbrook P, Gazzard B, Phillips AN; UK Collaborative HIV Cohort (UK CHIC) Study Group. Sabin CA, et al. Among authors: fisher m. BMJ. 2005 Mar 26;330(7493):695. doi: 10.1136/bmj.38369.669850.8F. Epub 2005 Mar 4. BMJ. 2005. PMID: 15749728 Free PMC article.
5,545 results